Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
Launched by SCHÖN KLINIK BERCHTESGADENER LAND · Oct 16, 2014
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
Patients will be recruited during a 3-week inpatient pulmonary rehabilitation program. They will perform the following three interventions on consecutive days and will repeat them after a week. During these days the time table for prescribed physical activities and therapies will be kept in a comparable fashion.
The following 3 interventions will be performed in randomized order:
Day A: The Patient wears a conventional nasal cannula for 12 h with oxygen flow rate as prescribed during ADL
Day B: The Patient wears the Oxymizer® with prescribed oxygen flow rate for 12 h during ADL
Day C: T...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • IPF patients with indication for long term oxygen therapy ≥ 2l/min
- • VC \>30% and \< 70% pred.
- Exclusion Criteria:
- • failure to comply with study process
- • acute infection
About Schön Klinik Berchtesgadener Land
Schön Klinik Berchtesgadener Land is a leading healthcare institution specializing in orthopedic and rehabilitation medicine, located in the picturesque Berchtesgaden region of Germany. Renowned for its patient-centered approach, the clinic combines state-of-the-art medical technology with a holistic treatment philosophy, aiming to enhance recovery and improve the quality of life for its patients. As a clinical trial sponsor, Schön Klinik Berchtesgadener Land is committed to advancing medical research and innovation, conducting rigorous studies that contribute to the development of effective therapeutic solutions in musculoskeletal health and beyond. The institution fosters collaborations with academic and industry partners to ensure the highest standards of clinical research and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Schoenau Am Koenigssee, Bayern, Germany
Patients applied
Trial Officials
Klaus Kenn, Dr. med
Study Chair
Schoen Klinik BGL
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials